Biote Corp. Class A Common Stock (BTMD)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages and conservative finances. Biote trains medical practices in hormone optimization using bioidentical pellet therapy. In FY2025 (the year ended 2025-12-31), the company reported revenue of $192.2M, net income of $27.0M, and diluted EPS of $0.74. That was a sharp rebound from FY2024 (the year ended 2024-12-31), when net income was only $3.2M on $197.2M of revenue. But the trend has weakened: in fiscal Q2 2026 (the quarter ended 2026-06-30), revenue was $44.2M with a net loss of $6.6M and diluted EPS of -$0.23, versus fiscal Q2 2025 (the quarter ended 2025-06-30) revenue of $48.9M and net income of $3.2M. Fiscal Q1 2026 net income was $2.3M, so results are erratic. At the 2026-10-13 close of $1.04, FairStock calculates a market cap of $29.8M, a P/E of 7.43, EV/EBITDA of 6.28, ROCE of 13.70%, and a TTM FCF yield of 58.9% on $17.5M of free cash flow. Statistically that looks cheap. Yet FairStock's Piotroski F-Score is 3/9 and Altman Z-Score is -0.12, which point to financial fragility. The Lynch category is TURNAROUND, returned to profit after a loss within the last three years. I see no clear moat in these figures, only a small niche provider with volatile earnings. A Graham-style margin of safety would require evidence that the recent loss is temporary and that cash flow is durable; the current price near the 52-week low of $1.00 offers neither comfort nor proof.

In plain English: Biote Corp. trains medical practices to offer hormone replacement pellet therapy. The business was profitable in its latest full year but has recently turned to a quarterly loss while sales fell. At the 2026-10-13 close of $1.04, the price looks low compared with its reported cash flow, but the recent loss makes that cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer